Pharmaceutical company
Appears in 3 stories
Co-manufacturer of venetoclax (Venclexta); submitted the supplemental new drug application
On February 20, 2026, the FDA approved venetoclax and acalabrutinib for chronic lymphocytic leukemia (CLL), the most common adult leukemia in Western countries, with roughly 23,000 new American cases each year. In a trial of 867 patients, 77% remained cancer-free at three years.
Updated May 29
Decnupaz sponsor and manufacturer
The FDA approved AbbVie's Decnupaz on May 27 for blastic plasmacytoid dendritic cell neoplasm, an aggressive blood cancer. It strikes an estimated few hundred Americans a year. It's the second drug ever approved for the disease and the first doctors can start in an outpatient clinic.
Updated May 28
Marketing first-approved presbyopia drop Vuity
For 240 years, reading glasses have treated presbyopia—the gradual loss of near vision that affects nearly everyone over 45—unchanged since Benjamin Franklin invented bifocals in 1785. Two billion people worldwide still rely on reading glasses today. On January 29, 2026, the FDA approved YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution), the first dual-agent eye drop for presbyopia.
Updated May 23
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
